Photo

613.801.0165

...

Ottawa

English, Russian

Vlad Levenets, Ph.D.

Patent Agent

Vlad joined MBM in June 2022 as a Patent Agent Trainee. Vlad’s practice focuses on patent drafting and prosecution of Canadian, US, and PCT applications in the field of telecommunication.

Vlad is a Registered Patent Agent in the United States and is currently working on becoming a Registered Canadian Patent Agent. While working in the US, Vlad's practice included patent drafting and prosecution, patentability analysis, and freedom-to-operate (FTO) and infringement opinions in a variety of technical fields, including wireless, semiconductor processing, FinFET, automotive electronics, MEMS sensors, 3D display, LIDAR/LADAR, photovoltaics.

Vlad’s doctoral work focused on new electronic materials, particularly silicon surface proton passivation. Vlad co-authored two dozen technical papers. He honed his extensive technical expertise while working for the Russian Space Agency, STMicroelectronics and Samsung Electronics.

In his spare time, Vlad enjoys reading books and watching movies.

Education:

  • MSc (Solid State Physics) - Moscow Engineering Physics Institute (Moscow, Russia)
  • Ph.D. (Electronics Engineering) - State Research Institute for Problems in Physics (Moscow, Russia)

Professional involvement:

  • Registered Patent Agent at the USPTO

Technology Areas:

  • Telecommunication
  • Electronics
  • Microfabrication
  • Optical
  • Mathematics
  • Physics

Practice Area

cb photo 124 561ead1bced0d

DR. POONAM TAUH

Patent Agent


Poonam’s focuses on the drafting and prosecution of pharmaceutical, chemical, biochemical, petrochemical, and polymer patent applications around the world.
MBM read_more_btn

 

MBM logo

About MBM

 The process of invention is complete only with the IP protection provided in law. That's where MBM comes in. We match our clients' creative thinking with the creative protection needed to achieve their goals.Read More About MBM

Clarifications to the Data Protection Guidance Document

Health Canada recently announced that section 2.1 of its Guidance Document re: Data Protection has been amended to clarify that the prior approval of a medicinal ingredient in a drug for veterinary use will not preclude the granting of data protection for a drug for...Read More